

1 **Altered neutrophil phenotype and function in non-ICU hospitalised COVID-19 patients**
2 **correlated with disease severity**

3
4
5 Belchamber KBR*¹, Thein OS*¹, Hazeldine J², Grudzinska FS¹, Hughes MJ¹, Jasper AE¹, Yip KP¹,
6 Sapey E^{1,3,4}, Parekh D¹, Thickett DR^{#1}, Scott A^{#1}.

7
8 *joint first author # joint senior author

9
10 ¹Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University
11 of Birmingham, B15 2TT, UK

12 ²National Institute for Health Research Surgical Reconstruction and Microbiology Research
13 Centre, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, United
14 Kingdom.

15 ³PIONEER HDR-UK Hub in acute care, Institute of Inflammation and Ageing, University
16 of Birmingham, B15 2TT, UK

17 ⁴NIHR Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust,
18 Edgbaston, Birmingham, B12 2GW

19
20 **Corresponding author:**

21 Professor David Thickett, Institute of Inflammation and Ageing, University of Birmingham,
22 Birmingham B15 2TH, UK; d.thickett@bham.ac.uk. [+44 \(0\)121 371 3257](tel:+441213713257)

23
24 **Author contributions:** Concept and design: KBRB, OST, JH, ES, DP, DRT, AS. Neutrophil work:
25 KBRB, OST. Patient recruitment: OST, FSG, KPY. Additional laboratory work: MJH, AEJ, AS.
26 Drafting manuscript: KBRB, OST, ES, DP, DRT, AS. All authors have read and approved the
27 manuscript.

28
29 This article has an online supplement.

30
31 **Sources of funding:** OST/DT/DP; Birmingham Health partners, KBRB/ES; Alpha One
32 Foundation (617303), JH; National Institute for Health Research (NIHR) Surgical
33 Reconstruction and Microbiology Research Centre, ES/KYP; British Lung Foundation

34 (PPRG16), DT/AS/ES/FSG; Dunhill trust (RTF1906\86), ES; Health Data Research-UK, DT/DP;
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 Health Technology Assessment, DT/AS/ES; Health Technology Assessment (NIHR129593),

36 DT/AS/ES; Medical Research Council (MR/L002736/1).

37

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71

Abstract word count: 250

Total word count: 3188

Abstract

Rational: Infection with the SARS-CoV2 virus is associated with elevated neutrophil counts. Evidence of neutrophil dysfunction in COVID-19 is based predominantly on transcriptomics or single functional assays. Cell functions are interwoven pathways, and so understanding the effect of COVID-19 across the spectrum of neutrophil function may identify tractable therapeutic targets.

Objectives: Examine neutrophil phenotype and functional capacity in COVID-19 patients versus age-matched controls (AMC)

Methods: Isolated neutrophils from 41 hospitalised, non-ICU COVID-19 patients and 23 AMC underwent *ex vivo* analyses for migration, bacterial phagocytosis, ROS generation, NET formation (NETosis) and cell surface receptor expression. DNase 1 activity was measured, alongside circulating levels of cfDNA, MPO, VEGF, IL-6 and sTNFRI. All measurements were correlated to clinical outcome. Serial sampling on day 3-5 post hospitalisation were also measured.

Results: Compared to AMC, COVID-19 neutrophils demonstrated elevated transmigration ($p=0.0397$) and NETosis ($p=0.0366$), but impaired phagocytosis ($p=0.0236$) associated with impaired ROS generation ($p<0.0001$). Surface expression of CD54 ($p<0.0001$) and CD11c ($p=0.0008$) was significantly increased and CD11b significantly decreased ($p=0.0229$) on COVID-19 patient neutrophils. COVID-19 patients showed increased systemic markers of NETosis including increased cfDNA ($p=0.0153$) and impaired DNase activity ($p<0.0001$). MPO ($p<0.0001$), VEGF ($p<0.0001$), TNFRI ($p<0.0001$) and IL-6 ($p=0.009$) were elevated in COVID-19, which positively correlated with disease severity by 4C score.

Conclusion: COVID-19 is associated with neutrophil dysfunction across all main effector functions, with altered phenotype, elevated migration, impaired antimicrobial responses and elevated NETosis. These changes represent a clear mechanism for tissue damage and highlight that targeting neutrophil function may help modulate COVID-19 severity.

72 **Introduction**

73 Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
74 coronavirus 2 (SARS-CoV2) virus, was declared a global pandemic by The World Health
75 Organisation on 11th March 2020 [1]. Up to 80% of people infected with SARS-CoV2
76 experience mild to moderate respiratory disease, but in 10-20% of cases, infection can
77 manifest as pneumonitis, with 5% progressing to acute respiratory distress syndrome (ARDS).
78 The overall worldwide mortality rate is 2.2% but this increases to up to 50% in the presence
79 of ARDS [2].

80
81 Dysregulated virus induced host-immune responses are thought to be the primary cause of
82 severe COVID-19 [3]. Neutrophils are frontline effector cells that protect against rapidly
83 dividing pathogens and play a pivotal role in the antiviral immune response [4]. Early during
84 an inflammatory event, neutrophils migrate into lung tissue where they perform phagocytosis
85 and release proteases, reactive oxygen species (ROS) and as a later response, neutrophil
86 extracellular traps (NETs) to aid clearance of infection [5].

87
88 Advanced age is a recognised risk factor for severe COVID-19, including the development of
89 ARDS [6-8]. Ageing is associated with changes in neutrophil function, including reduced
90 migratory accuracy [9], phagocytosis [10] and NETosis [11], which may delay pathogen
91 clearance and increase bystander tissue injury. Further impairments in neutrophil function
92 have been observed in patients with pneumonia [12], sepsis [13] and ARDS [14]. This
93 dysfunction is most apparent in older adults with severe infections [15] and is associated with
94 poor clinical outcomes [12, 13]. Importantly, these functional deficits appear amenable to
95 therapeutic correction, especially in early or less severe infective episodes, suggesting that
96 neutrophils, or their products, may form a tractable target in inflammatory disease [16, 17].
97 There is some evidence that neutrophil dysfunction could be associated with distinct cellular
98 phenotypes within the neutrophil population, with immature, senescent, activated and pro-
99 inflammatory neutrophils identified in age and disease [13, 18, 19].

100
101 Emerging studies suggest that neutrophils are implicated in the pathogenesis of severe
102 COVID-19 and every reporting study has described cell dysfunction (or inferred cell
103 dysfunction through transcriptomics) which could contribute to tissue damage and secondary
104 infection [20-27] However, studies have often been small, fail to provide age-matched
105 controls, assess patients on the intensive care unit (ICU) after a considerable delay since
106 symptom onset, and often consider neutrophil functions in isolation.

107
108 These are important considerations. As neutrophil functions change with age, age matched
109 controls are important to identify pathological differences. Although approximately 12% of
110 hospitalised COVID-19 require ICU support, the majority of hospital admissions and deaths
111 occur on non-ICU wards [28]; understanding how to improve outcomes for this patient group
112 is vital. Most studies in sepsis have demonstrated cell function is more therapeutically
113 tractable during early disease (before ICU care is needed), so the timeliness of intervention is
114 important. Cell functions are enabled by interwoven cell pathways with important differences
115 in internal signalling; knowing which functions are impaired informs which therapeutic
116 strategies might restore/maintain all facets of cellular function.

117

118

119
120 We hypothesised that neutrophils from COVID-19 patients would exhibit diverse altered
121 effector functions and changes to phenotype, with the degree of dysfunction associated with
122 adverse patient outcomes.

123
124 This study aimed to perform, for the first time, a comprehensive assessment of *ex vivo*
125 neutrophil phenotype and function in a statistically powered cohort of hospitalised, non-ICU
126 SARS-CoV2 infected patients compared to aged-matched controls and investigate
127 relationships with clinical outcomes.

128
129 **Methods**

130 **Healthy donor and patient recruitment**

131 Recruitment is summarised in Figure 1. COVID-19 patients were recruited January to March
132 2021 from the Queen Elizabeth Hospital Birmingham, in accordance with ethics REC ref:
133 19/WA/0299 and 20/WA/0092 approved by the West Midlands – Solihull research ethics
134 committee. Written informed consent was obtained where possible; patients unable to
135 consent due to lack of capacity were consented by proxy; designated consultee via telephone
136 or professional consultee. Follow-up samples were collected at days 3-5 with confirmed
137 consent, where possible.

138
139 Patients were recruited within 48 hours of hospital admission due to pneumonitis/pneumonia
140 related to COVID-19. All patients had a positive COVID-19 PCR swab. No patients received
141 novel treatments or were part of a COVID clinical medicinal trial on recruitment to this study.
142 Exclusion criteria were admission outside timeframe, no evidence of
143 pneumonia/pneumonitis, long-term oral steroid use, haematological malignancy causing
144 neutropenia, any cause of immunosuppression, recruitment into a trial for novel therapy,
145 admission to ITU, palliative or imminent treatment withdrawal within 24 hours and
146 pregnancy. Patients with COPD or asthma were excluded due to known alterations in
147 neutrophil function in these patient groups [29]. COVID-19 patients were stratified using the
148 4C Mortality Score for COVID-19, separated by scores <9 and ≥9 (in-hospital mortality <9.9%
149 and >31.4% respectively) [30]. Patients were classified with ARDS based on the Berlin criteria;
150 SpO₂: FiO₂ ratio (SF), converted to PaO₂: FiO₂ (PF) (SF=57-0.61PF).

151
152 Age matched controls (AMC) were either recruited from patients attending pre-booked face-
153 to-face outpatient appointments or from hospital staff. AMC had no evidence of acute illness
154 including COVID-19 within the last two weeks, as assessed by a respiratory physician, and met
155 the other exclusion criteria described above.

156
157 Additional details on methodology are provided in the online supplement. These methods
158 include; plasma collection, neutrophil isolation by Percoll gradient centrifugation,
159 phagocytosis of fluorescent *S. pneumoniae*, NETosis by release of cell-free (cf)DNA, transwell
160 migration, phenotyping by flow cytometry, serum DNase-1 activity assay, plasma cfDNA
161 quantification, citrullinated histone H3 detection and plasma biomarker quantification.

162
163 **Statistics**

164 Statistical analysis is described in the online supplement. A power calculation performed on
165 isolated neutrophil NETosis data (80%, alpha 0.05) suggested 18 participants were required

166 in each group (see supplement for details). Data are presented throughout as median (IQR),
167 with each n number representing a separate study participant. Significance was defined at p
168 <0.05. There were no corrections for multiple comparisons but exact p values are given.

169

170

171 **Results**

172

173 ***Clinical characterisation***

174 41 COVID-19 patients (mean age 69.9 years) and 23 healthy AMC (mean age 69.7 years) were
175 included in the study. Demographics are provided in Table 1. COVID-19 patients were
176 admitted to hospital 7 days (range 3-14) after symptom onset and were recruited to the study
177 after median 2 days (range 1-2). Length of hospital stay was 7.7 days (survivors 7.5 days, non-
178 survivors 9.1 days) and the mortality rate was 24% (10/41). 38/41 patients received
179 dexamethasone as part of their acute treatment as per standard of care [31]. 17/41 patients
180 had ARDS as defined by the Berlin criteria with the exception of ventilation pressure [32], and
181 of these 8 had moderate to severe ARDS.

182

183 ***Neutrophil migration is elevated through a transwell system in COVID-19***

184 Neutrophils from COVID-19 patients demonstrated increased transwell migration towards
185 CXCL-8 compared to AMC (Fold change of neutrophils migrated to CXCL-8 vs. vehicle control:
186 12.15 (51.4) AMC vs. 40.63 (115.2) COVID-19, p=0.0397, Figure 2A). Migration was not
187 associated with 4C score (p=0.5575, Supplementary Figure 5A), or survival at 28 days
188 (p=0.2563, Supplementary Figure 6A). There was no change in migration at follow up
189 (p=0.1641, Supplementary Figure 4A).

190

191 ***Neutrophil phagocytosis is impaired in COVID-19***

192 Neutrophil phagocytosis of *S. pneumoniae* was significantly decreased in COVID-19 patients
193 compared to AMC (Median fluorescence intensity (MFI): 8.0 (4.2) AMC vs. 6.6 (2.6) COVID-19,
194 p<0.0236, Figure 2B). Phagocytosis was not associated with 4C score (p=0.3257,
195 Supplementary Figure 5B) or survival at 28 days (p=0.9228, Supplementary Figure 6B). There
196 were no differences in neutrophil viability between patient groups or treatment conditions
197 (p=0.6726, Supplementary Figure 3A).

198

199 ***Neutrophil derived ROS generation following phagocytosis is impaired in COVID-19***

200 Cytoplasmic (c)ROS, and nuclear/mitochondrial (n/m)ROS were measured in resting
201 neutrophils and following phagocytosis. Compared to unstimulated cells, cROS levels were
202 elevated after phagocytosis in both AMC (MFI: 46.8 (28) baseline vs. 64.9 (51) 30 minutes,
203 p<0.0005) and COVID-19 patients (MFI: 44.1 (35) baseline vs. 65.3 (60) 30 minutes, p=0.0235).
204 However, no differences were observed in cROS levels in either resting (p=0.999) or
205 stimulated (p=0.3946) neutrophils between study groups (Figure 2C).

206

207 Compared to resting neutrophils, n/mROS levels were significantly higher after phagocytosis
208 in neutrophils isolated from AMC (MFI: 21.8 (21) baseline vs. 32.0 (38), p<0.0001), but not in
209 COVID-19 patients (MFI: 18.9 (12) baseline vs. 21.2 (12), p=0.0610). No significant differences
210 were found in the levels of n/mROS in resting neutrophils (MFI: 21.8 (21) AMC vs. 18.9 (12)
211 COVID-19, p=0.0610). However, reduced levels of n/mROS were measured in neutrophils

212 isolated from COVID-19 patients following phagocytosis when compared to AMC (MFI: 32.0
213 (38) AMC vs. 21.2 (12) COVID-19, $p < 0.0001$, Figure 2D).

214

215 **Neutrophil NETosis is elevated in COVID-19**

216 Higher levels of cfDNA were detected in supernatants obtained from COVID-19 patient
217 neutrophils post-PMA treatment compared to AMC (fold change in absorbance of neutrophils
218 stimulated with PMA vs. vehicle control: 1.29 (0.32) AMC vs. 1.53 (1.66) COVID-19, $p = 0.0366$,
219 Figure 3A). There were no differences in resting neutrophils NET production between COVID
220 patients and AMC (Supplementary Figure S3). When COVID-19 patients were stratified by
221 disease severity, more severe disease was associated with increased NETosis (fold change:
222 1.17 (0.35) Low 4C vs. 1.41 (0.80) High 4C, $p = 0.0118$, Figure 3B).

223

224 At hospital admission, COVID-19 patients presented with higher concentrations of plasma
225 cfDNA compared to AMC (621ng/ml (1324) AMC vs. 1071ng/ml (856) COVID-19, $p = 0.0153$,
226 Figure 3C), which persisted at Day 3-5 day ($p = 0.0186$, Figure. 3D).

227

228 To determine whether neutrophils, via NETosis, were a source of the cfDNA, plasma samples
229 were screened for the presence of CitH3, a protein that decorates the DNA backbone of NETs
230 [33]. Western blotting revealed the presence of CitH3 in 6 out of 8 samples analysed (75%,
231 Supplementary Figure 7).

232

233 Using NETs as a substrate, serum DNase activity was lower in COVID-19 patients at the time
234 of hospital admission when compared to AMCs (% degradation: 88.4% (93) AMC vs. 12.8%
235 (49), $p < 0.0001$, Figure 3E).

236

237 **Neutrophil phenotype is altered in COVID-19**

238 To determine whether changes observed in neutrophil function were associated with
239 phenotype, surface expression of key surface molecules were investigated by flow cytometry.
240 A table of percentage receptor expression and MFI is shown in table 2.

241

242 Both the percentage of neutrophils expressing the activation marker CD11b (81% (8.9) AMC
243 vs. 67.8% (43.9) COVID-19, $p = 0.0229$), and its surface expression (MFI: 343 (119) AMC vs. 40
244 (141) COVID-19, $p = 0.0003$, Figure 4A) were reduced in COVID-19 patients. Expression of the
245 adhesion molecule CD11c was also elevated in COVID-19 patients (MFI: 220 (1274) AMC vs.
246 1148 (670) COVID-19, $p < 0.0008$, Figure 4B).

247

248 Both the percentage of neutrophils expressing CD54, a marker of reverse transmigration
249 (33.4% (35.3) AMC vs. 71.3% (21.2) COVID-19, $p < 0.0001$, Figure 4C) and its surface expression
250 (MFI: 21 (38) AMC vs. 73 (58) COVID-19, $p = 0.0008$ Figure 4D) were elevated in COVID-19
251 patients.

252

253 Expression of CD66b, CD62L, CD10, CXCR2, CXCR4 and PD-L1 did not differ between AMC and
254 COVID-19 patients (see table 2). There was no association of neutrophil phenotypic marker
255 expression with 4C severity score, or in survivors and non-survivors.

256

257 On day 3-5 follow-up, relative to baseline readings, there was a decrease in CXCR2 expression
258 (MFI: 1960 (1601) Day 1 vs. 1126 (1262) Day 3-5, $p = 0.0322$, Figure 4E) and a significant

259 increase in CXCR4 expression (MFI: 1785 (3951) Day 1 vs. 10248 (16483) Day 3-5, $p=0.0273$,
260 Figure 4F). The percentage of cells expressing CD54 was significantly reduced at 3-5 day follow
261 up (80.6% (34.6) Day 1 vs. 58.9% (38.3) Day 3-5, $p=0.0420$, Figure 4G)

262

263 **Systemic inflammatory mediators are elevated in COVID-19**

264

265 COVID-19 patients showed elevated levels of IL-6 ($p<0.009$, Figure 5A), VEGF ($p<0.0001$,
266 Figure 5B), sTNFRI ($p<0.0001$, Figure 5C), and MPO ($p<0.0001$, Figure 5D), but not GM-CSF
267 ($p=0.3375$, Figure 5E) when compared to AMC.

268

269 Only 2/41 COVID-19 patients demonstrated a hyperinflammatory phenotype when stratified
270 using the algorithm developed to classify non-COVID ARDS phenotypes [34].

271

272 IL-6 and sTNFRI concentrations were higher in non-survivors versus survivors ($p=0.0027$,
273 $p=0.0420$ respectively, Supplementary Figure. 6) and raised in those patients with a 4C score
274 ≥ 9 (IL-6 $p=0.0059$, sTNFRI $p=0.0478$, Supplementary Figure. 5).

275

276 IL-6 levels were significantly raised in patients with moderate to severe ARDS compared to
277 mild ($p=0.0468$, Supplementary Figure. 6). We observed no associations between the severity
278 of ARDS and VEGF ($p=0.1164$) or sTNFRI ($p=0.3953$).

279

280

281 **Discussion**

282 We present novel findings of COVID-associated neutrophil dysfunction, across all main
283 effector functions. In summary, compared to AMC, systemic neutrophils from patients
284 hospitalised with moderate severity COVID-19 demonstrated increased migration, impaired
285 anti-microbial responses including reduced phagocytosis and nuclear/mitochondrial ROS
286 generation after phagocytosis. Later/end phase neutrophil responses were increased, namely
287 *ex-vivo* NETosis with evidence of increased systemic NETosis, coupled with reduced DNase
288 activity. We also show an altered but distinct neutrophil phenotype, not compatible with a
289 purely activated, immature, senescent or anti-inflammatory phenotype as described before
290 (summarised in Figure 6). Our data suggests the energetics of the cells were not overtly
291 compromised, as some "high energy-consuming" functions (such as migration [35]) were
292 elevated. Of note, some of these changes have been described by authors studying COVID-19
293 before the widespread use of dexamethasone as standard of care [27, 36], suggesting our
294 results are not a treatment effect.

295

296 Individually, as described in other studies, these changes to effector function could
297 compromise aspects of host defence. Collectively, these changes represent a clear
298 mechanism for significant tissue damage. Poor phagocytosis would impede pathogen
299 clearance, increasing the likelihood of secondary infection and amplifying inflammation.
300 NETosis is implicated in tissue damage and thrombotic events in several disease settings [37,
301 38]. The inability to clear NETs through reduced DNase activity would further augment
302 NETosis-associated tissue damage [39].

303

304 Secondary infection in COVID-19 is associated with increased severity of lung disease and
305 poorer outcomes [40, 41]. Impaired neutrophil antimicrobial responses towards *S.*
306 *pneumoniae*, the most common bacteria implicated in secondary infection in COVID-19 [42],
307 alongside impaired intracellular ROS generation important for phagosomal bacterial killing
308 [43], may contribute to the incidence of secondary infection and poorer outcomes for these
309 patients.

310
311 Elevated NETosis [23, 24, 44] and increased systemic concentrations of cfDNA [23, 24] have
312 been described previously in small numbers of COVID-19 patients. Our observation of
313 reduced serum DNase activity builds on studies showing reduced plasma concentrations of
314 Gelosin in COVID-19; Gelosin depolymerises filamentous actin, an inhibitor of DNase activity
315 [45-47]. Thus, a circulating microenvironment dominated by negative regulators of DNase-1
316 could offer a potential mechanistic explanation for the impaired DNase-1 activity we report,
317 with elevated NETosis contributing to host tissue damage and thrombotic events.

318
319 The collective pattern of neutrophil dysfunction in COVID-19 speaks of alterations to
320 mechanosensing within these cells. Elevated migration and impaired phagocytosis could both
321 be linked to reduced pseudopod extrusion, which is known to increase migratory speed [48].
322 Also, pseudopods are involved in phagocytosis, with reorganisation of the cell composition to
323 enable bacterial engulfment [49]. Phosphoinositide 3-kinase (PI3K) is a key intracellular
324 signalling molecule involved in chemotaxis, cytoskeletal rearrangement for phagocytosis, and
325 superoxide generation [50] and has most recently been implicated in NETosis [51]. Aberrant
326 PI3K signalling is linked to increasing age, and PI3K inhibitors have been show to improve
327 neutrophil migratory accuracy in the elderly [9], while reducing NET formation *ex vivo* [52,
328 53]. This suggests there might be tractable targets across neutrophil cellular functions, which
329 could be manipulated to enhance some responses (phagocytosis) while reducing others
330 (NETosis), and to improve innate immune responses in COVID-19.

331
332 We observed an altered neutrophil phenotype in moderate COVID-19, not compatible with
333 previously described populations. COVID-19 neutrophils expressed decreased levels of the
334 activation marker CD11b and a lack of CD62L shedding, which has previously been observed
335 in sepsis [54]. We saw elevated expression of the immunosuppressive marker CD11c, also
336 elevated in sepsis [54], but no changes in the expression of CD10; a marker of immature
337 neutrophils [55], or CXCR2 and CXCR4; markers of senescence [56]. This contrasted with
338 RNAseq studies that reported populations of immature and senescent neutrophils in severe
339 COVID-19 patients compared to mild patients or non-AMC [22, 57]. Our contrasting data from
340 moderate COVID-19 patients suggests that either the duration of COVID-19 infection or the
341 extreme severity of infection (from not requiring, to requiring organ support) affects cellular
342 dysfunction and, as in pneumonia and sepsis [17], may support a window for therapeutic
343 intervention.

344
345 Finally, we observed that COVID-19 neutrophils expressed elevated CD54, a marker of reverse
346 transmigration, whereby neutrophils migrate from the tissues back into the circulation. These
347 cells are capable of high levels of oxidative burst [58], which may contribute to high levels of
348 NETosis. By day 3-5 post-admission, we report increased levels of senescent CXCR4⁺ CXCR2⁻
349 neutrophils, confirming a report of reduced CXCR2⁺ neutrophils in ICU COVID-19 patients [59].

350

351 The majority of COVID-19 hospitalisations and deaths occur in non-ICU wards [28], making
352 this cohort important for targeted intervention. While there was evidence of systemic
353 inflammation, indicated by elevated levels of circulating IL-6, sTNFRI and VEGF, less than 5%
354 of the patients in the current study met the criteria for the hyper-inflammation phenotype
355 described in ARDS [34] and had levels of circulating mediators lower than described in “usual”
356 sepsis [13]. IL-6 and CXCL-8, as well as platelet derived factors and antigen-antibody
357 complexes are thought to drive NET formation, providing another mechanism to link systemic
358 inflammation to neutrophil dysfunction [60-62].

359
360 Our data suggests a distinct cellular response in moderate COVID-19 which contribute to on-
361 going immune mediated harm, but which may be modifiable using a targeted therapy given
362 administered at this crucial point in disease progression. While *ex vivo* experiments suggest
363 PI3K inhibition may improve all aspects of neutrophil dysfunction described in the current
364 study [52, 53], this has not tested in COVID-19 patients. The STOP-COVID trial (Superiority
365 Trial Of Protease inhibition in COVID-19, NCT04343898) is assessing the ability of Brensocatib
366 to reduce neutrophil serine protease activity in COVID-19. Brensocatib improves clinical
367 outcomes in bronchiectasis patients by reducing neutrophil proteases systemically [63], and
368 may reduce the consequences of elevated NETosis in COVID-19, described in the current
369 study.

370
371 Our data complements studies which showed increased systemic NETosis in COVID-19 [24,
372 64], and elevates those which show increased NETosis in isolated neutrophils, by including
373 increased patient numbers and appropriate AMC [23, 24, 44]. A study by Masso-Silva *et al.*
374 recently showed elevated neutrophil phagocytosis in sixteen ICU COVID-19 patients
375 compared to non-AMC. Differing results may be due to the differing experimental techniques,
376 disease severity and patient numbers. Their study used polymorphoprep rather than Percoll®
377 to isolate neutrophils, and the authors combined data from multiple blood samples taken
378 over eleven days of hospitalisation. As we show changes in neutrophil phenotype and
379 function over the 3-5 time course of our study, we suggest that combining time points
380 obscures the complex changes occurring in this short-lived cell population. We also used
381 opsonised *S. pneumoniae* for phagocytosis studies, which may be phagocytosed by different
382 mechanisms to *S. aureus* bioparticles [49], confounding results.

383 384 *Limitations*

385 This study was limited due to the safety measures required. All experiments were carried out
386 within a BSL2 hood and methods chosen based on tolerance to inactivation/fixation with 4%
387 PFA. Our patients did not include an ICU group, however, mild-moderate disease forms a
388 larger proportion of overall COVID-19 patients, and we believe it is this point in the patient
389 pathway which holds most potential for successful intervention.

390 391 *Conclusion*

392 Our study shows that moderate COVID-19 is associated with alterations in neutrophil
393 phenotype, increased migratory capacity and NETosis, and impaired antimicrobial function
394 which contributes to the severity of COVID-19. Elevated NETosis in the lung is associated with
395 disease severity, and elevated systemic NET production is likely to contribute to inflammation,
396 which may drive ARDS associated damage, and thrombosis. Targeting neutrophils and their
397 downstream effectors may be beneficial in the treatment of COVID-19.

	AMC N=23	COVID-19 N=41	COVID-19 4C ≤8 N=10	COVID-19 4C ≥9 N=31	COVID-19 Follow up N=12	Survived to discharge N=31	Died N=10
Male:Female	8:15	26:15	7:3	18:12	5:7	19:12	7:3
White:non-white	22:1	31:10	7:3	23:8	10:2		
Died (%)	0 (0%)	10 (24%)	0 (0%)	10 (32%)	4 (33%)	0 (0%)	10 (100%)
Age	68 (61-78)	71.5 (58-84)	78 (69-87)	71 (58-84)**	83 (77.8-90.0)	61 (56-78)	87 (79-90)**
BMI (kg/m ²)		26.4 (24.2-32.8)	31.26 (30.0-36.9)	25.39 (23.3-31.9)*	24.7 (21.8-26.1)	29.7 (24.3-33.3)	25.7 (23.8-28.5)
Comorbidity							
Cardiovascular	4 (17.4%)	12 (29.3%)	3 (30%)	9 (29.0%)	4 (33.3%)	7 (22.6%)	8 (80%)*
Respiratory	0 (0%)	1 (2.4%)	0 (0%)	1 (3.2%)	0 (0%)	2 (6.5%)	2 (20%)
Endocrine	7 (30.4%)	16 (39.0%)	3 (30%)	13 (41.9%)	5 (41.7%)	12 (38.7%)	5 (50%)
Hypertension	12 (52.2%)	19 (46.3%)	0 (0%)	19 (61.3)**	7 (58.3%)	10 (32.2%)	9 (90%)*
Other	11 (47.8%)	24 (58.5%)	1 (10%)	23 (74.2%)**	8 (66.7%)	8 (25.8%)	6 (60%)
WCC (x10 ⁹ /L)		8.2 (6.3-12.0)	7.1 (6.1-9.7)	8.8 (6.8-12.5)	12 (9.2-20.3)	8.2 (6.4-10.8)	8.3 (6.3-24.8)*
Neutrophils (x10 ⁹ /L)		6.4 (4.4-8.6)	5.5 (4.3-8.0)	6.7 (4.6-8.8)	9.7 (6.6-12.2)	6.5 (4.5-8.4)	5.8 (4.0-17.3)
CRP (mg/L)		103.0 (63.0-165.0)	86.0 (44.3-158.3)	116.0 (72.0-170.0)	50.5 (17.5-147.3)	98.0 (57.5-155.0)	139.0 (68.5-202.8)
NLR		5.4 (3.8-10.8)	5.4 (3.7-7.5)	4.5 (3.9-13.3)	10.43 (6.7-23.5)	6.3 (3.6-12.1)	4.9 (4.0-11.5)
Worst NEWS2		6.0 (5.0-7.0)	6 (5.3-7.0)	6.0 (4.3-7.0)	4 (3.8-5.8)	6.0 (4.5-7.0)	7.0 (7.0-9.5)
HS Troponin I (ng/L)		14.5 (5.0-31.3)	<5 (<5-5.0)	18.0 (9.0-37.0)		7.0 (5.0-15.5)	17.5 (11.8-37.0)**
D-dimer (ng/mL)		382.0 (218.0-829.5)	267.0 (201.0-572.0)	408.5 (233.0-886.5)		382.0 (242.5-825.0)	300.5 (182.8-3003.3)
Ferritin (µg/L)		1082 (428.3-1525.0)	1169 (569.0-1377.0)	995 (394.0-2055.5)		1260 (548.3-1531.0)	431 (371.0-2187.3)
Vitamin D (nmol/L)		35.6 (23.0-51.8)	25.3 (18.3-36.0)	45.0 (25.6-70.1)**	52.6 (45.4-67.8)	32.9 (21.4-56.9)	57.9 (29.6-86.5)**
Dexamethasone		38 (92.6%)	10 (100%)	28 (90.3%)	10 (83.3%)	28 (90%)	10 (100%)
Admission 4C		12 (9.0-14.0)			13 (11.0-14.8)*	10.0 (6.5-13.0)	16 (13.3-20.0)**
qSOFA		1 (1.0-1.5)	1 (0.3-1.0)	1 (1.0-2.0)	1 (0.0-1.0)	1 (0.5-1.0)	1.5 (1.0-2.0)
SOFA		1 (0.0-3.5)	0 (0.0-1.25)	2 (0.5-4.0)		1 (0.0-2.0)	4 (3.0-5.0)**
Length of stay (days)		5.5 (3.0-12.0)	3.0 (2.0-4.0)	9.5 (4.3-12.0)*		4.0 (2.3-12.0)	9.5 (6.3-12.0)
Presenting complaint							
Cough		31 (75.6%)	9 (90%)	22 (71.0%)		23 (74.2%)	8 (80%)
Anosmia		5 (12.2%)	2 (20%)	3 (9.7%)		5 (16.1%)	0 (0%)
Pyrexia		12 (29.2%)	5 (50%)	7 (22.6%)		11 (35.5%)	1 (10%)
Confusion		14 (34.1%)	0 (0%)	14 (44.2%)		6 (19.4%)	8 (80%)**

Myalgia	17 (41.5%)	7 (70%)	10 (32.6%)	14 (45.2%)	3 (30%)
---------	------------	---------	------------	------------	---------

399

400

401 Table 1. Patient demographic details. Data was collected at the time of recruitment. \pm values
 402 indicate SD. WCC- White cell count; CRP- C-reactive protein; NLR- neutrophil: lymphocyte
 403 ratio; NEWS2- National Early Warning Score2; HS Troponin I- high sensitivity troponin I; 4C-
 404 4C Mortality Score for COVID-19; qSOFA- quick Sepsis-related Organ Failure Assessment;
 405 SOFA- Sepsis-related Organ Failure Assessment. * <0.05 , ** <0.001 , *** <0.0001 , normally
 406 distributed results shown with mean \pm SEM, not normally distributed results shown with
 407 median (IQR Q1-Q3). Other diagnoses were included if they constituted significant impact on
 408 quality of life or regular medication, included but not limited to: severe peripheral vascular
 409 disease with active ulceration, dementia, chronic kidney disease, stroke, rheumatoid arthritis,
 410 childhood polio, diverticulosis, obesity, alcohol liver disease.

411

Receptor	% expression			MFI		
	AMC N=22	COVID N=34	P value	AMC N=22	COVID N=34	P value
CD10	95.1 (7.72)	95.3 (13.6)	0.977	669 (697)	836 (518)	0.623
CD11b	81.0 (8.9)	67.8 (43.9)	*0.0229	343 (119)	40 (223)	*0.005
CD54	33.4 (35.3)	71.3 (21.2)	*<0.0001	21 (38)	73 (58)	*0.008
CD62L	19.8 (14.7)	31.0 (15.3)	*0.0096	62 (46)	94 (121)	0.379
CXCR2	100 (0.1)	100 (0.2)	0.119	2472 (1632)	2031 (1600)	0.153
CXCR4	96.6 (11.3)	96.7 (9.07)	0.508	2216 (4130)	1724 (4177)	0.552
CD66b	99.8 (0.5)	99.8 (0.3)	0.770	257 (213)	186 (161)	0.353
CD11c	99.7 (1.65)	99.9 (1.05)	0.101	220 (1274)	1148 (670)	*0.008
PD-L1	99.6 (40.4)	98 (27.9)	0.452	157 (166)	70 (132)	0.093

412

413 **Table 2**

414 Percentage of cells expressing, or MFI of isolated neutrophil cell surface markers measured
 415 by flow cytometry in AMC (n=22) or COVID-19 patients (n=34). Data displayed as median

416 (IQR). Data analysed by individual Mann-Whitney test between AMC and COVID-19, with
417 significance shown in bold.

418
419

420 Acknowledgements

421

422 JH is supported by the National Institute for Health Research (NIHR) Surgical Reconstruction
423 and Microbiology Research Centre (SRMRC). The views expressed are those of the author(s)
424 and not necessarily those of the NIHR or the Department of Health and Social Care. Special
425 thanks to UK-Coronavirus immunology consortium.

426

427 References

428

- 429 1. Cucinotta, D. and M. Vanelli, *WHO Declares COVID-19 a Pandemic*. Acta Biomed, 2020. **91**(1): p. 157-160.
- 430 2. *WHO Coronavirus (COVID-19) Dashboard*. [cited 2021 13th May]; Available from:
431 <https://covid19.who.int>.
- 432 3. Dorward, D.A., et al., *Tissue-Specific Immunopathology in Fatal COVID-19*. Am J
433 Respir Crit Care Med, 2021. **203**(2): p. 192-201.
- 434 4. Galani, I.E. and E. Andreakos, *Neutrophils in viral infections: Current concepts and*
435 *caveats*. J Leukoc Biol, 2015. **98**(4): p. 557-64.
- 436 5. Aulakh, G.K., *Neutrophils in the lung: "the first responders"*. Cell and tissue research,
437 2017. **371**: p. 577-588.
- 438 6. Zhang, G., et al., *Clinical features and short-term outcomes of 221 patients with*
439 *COVID-19 in Wuhan, China*. J Clin Virol, 2020. **127**: p. 104364.
- 440 7. Printz, C., *Poor COVID-19 outcomes and deaths linked to advanced age and pre-*
441 *existing conditions*. Cancer, 2021. **127**(4): p. 497.
- 442 8. Chen, Y., et al., *Aging in COVID-19: Vulnerability, immunity and intervention*. Ageing
443 Res Rev, 2021. **65**: p. 101205.
- 444 9. Sapey, E., et al., *Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in*
445 *the elderly: toward targeted treatments for immunosenescence*. Blood, 2014. **123**(2): p.
446 239-248.
- 447 10. Butcher, S.K., et al., *Senescence in innate immune responses: reduced neutrophil*
448 *phagocytic capacity and CD16 expression in elderly humans*. J Leukoc Biol, 2001.
449 **70**(6): p. 881-6.
- 450 11. Hazeldine, J., et al., *Impaired neutrophil extracellular trap formation: a novel defect in*
451 *the innate immune system of aged individuals*. Aging Cell, 2014. **13**(4): p. 690-8.
- 452 12. Grudzinska, F.S., et al., *Neutrophils in community-acquired pneumonia: parallels in*
453 *dysfunction at the extremes of age*. Thorax, 2020. **75**(2): p. 164-171.
- 454 13. Patel, J.M., et al., *Sepsis Induces a Dysregulated Neutrophil Phenotype That Is*
455 *Associated with Increased Mortality*. Mediators Inflamm, 2018. **2018**: p. 4065362.
- 456 14. Juss, J.K., et al., *Acute Respiratory Distress Syndrome Neutrophils Have a Distinct*
457 *Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition*. Am J Respir Crit
458 Care Med, 2016. **194**(8): p. 961-973.
- 459 15. Sapey, E., et al., *Pulmonary infections in the elderly lead to impaired neutrophil*
460 *targetting, which is improved by simvastatin*. American journal of respiratory and
461 critical care medicine, 2017. **196**(10).
- 462

- 463 16. Greenwood, J., L. Steinman, and S.S. Zamvil, *Statin therapy and autoimmune disease: from protein prenylation to immunomodulation*. *Nature reviews immunology*, 2006. **6**:
464 p. 358-370.
465
- 466 17. Sapey, E., et al., *Simvastatin Improves Neutrophil Function and Clinical Outcomes in*
467 *Pneumonia. A Pilot Randomized Controlled Clinical Trial*. *Am J Respir Crit Care Med*,
468 2019. **200**(10): p. 1282-1293.
- 469 18. Drew, W., D.V. Wilson, and E. Sapey, *Inflammation and neutrophil immunosenescence*
470 *in health and disease: Targeted treatments to improve clinical outcomes in the elderly*.
471 *Exp Gerontol*, 2018. **105**: p. 70-77.
- 472 19. Rosales, C., *Neutrophil: A Cell with Many Roles in Inflammation or Several Cell*
473 *Types?* *Front Physiol*, 2018. **9**: p. 113.
- 474 20. Wang, J., et al., *Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-*
475 *19*. *Front Immunol*, 2020. **11**: p. 2063.
- 476 21. Aschenbrenner, A.C., et al., *Disease severity-specific neutrophil signatures in blood*
477 *transcriptomes stratify COVID-19 patients*. *Genome Med*, 2021. **13**(1): p. 7.
- 478 22. Schulte-Schrepping, J., et al., *Severe COVID-19 Is Marked by a Dysregulated Myeloid*
479 *Cell Compartment*. *Cell*, 2020. **182**(6): p. 1419-1440.e23.
- 480 23. Middleton, E.A., et al., *Neutrophil extracellular traps contribute to immunothrombosis*
481 *in COVID-19 acute respiratory distress syndrome*. *Blood*, 2020. **136**(10): p. 1169-
482 1179.
- 483 24. Skendros, P., et al., *Complement and tissue factor-enriched neutrophil extracellular*
484 *traps are key drivers in COVID-19 immunothrombosis*. *J Clin Invest*, 2020. **130**(11): p.
485 6151-6157.
- 486 25. Zuo, Y., et al., *Neutrophil extracellular traps in COVID-19*. *JCI Insight*, 2020. **5**(11).
- 487 26. Arcanjo, A., et al., *The emerging role of neutrophil extracellular traps in severe acute*
488 *respiratory syndrome coronavirus 2 (COVID-19)*. *Sci Rep*, 2020. **10**(1): p. 19630.
- 489 27. Leppkes, M., et al., *Vascular occlusion by neutrophil extracellular traps in COVID-19*.
490 *EBioMedicine*, 2020. **58**: p. 102925.
- 491 28. Sapey, E., et al., *Ethnicity and risk of death in patients hospitalised for COVID-19*
492 *infection in the UK: an observational cohort study in an urban catchment area*. *BMJ*
493 *Open Respiratory Research*, 2020. doi: [bmjresp-2020-000644](https://doi.org/10.1136/bmjresp-2020-000644): p. 1 - 11.
- 494 29. Walton, G.M., et al., *Repurposing treatments to enhance innate immunity. Can statins*
495 *improve neutrophil functions and clinical outcomes in COPD?* *Journal of clinical*
496 *medicine*, 2016. **5**(10).
- 497 30. Knight, S.R., et al., *Risk stratification of patients admitted to hospital with covid-19*
498 *using the ISARIC WHO Clinical Characterisation Protocol: development and*
499 *validation of the 4C Mortality Score*. *Bmj*, 2020. **370**: p. m3339.
- 500 31. *COVID-19 rapid guideline: Managing COVID-19*, N.I.f.H.a.C. Excellence, Editor.
501 2021.
- 502 32. Ranieri, V.M., et al., *Acute respiratory distress syndrome: the Berlin Definition*. *Jama*,
503 2012. **307**(23): p. 2526-33.
- 504 33. Liu, C.L., et al., *Specific post-translational histone modifications of neutrophil*
505 *extracellular traps as immunogens and potential targets of lupus autoantibodies*.
506 *Arthritis Res Ther*, 2012. **14**(1): p. R25.
- 507 34. Sinha, P., et al., *Development and validation of parsimonious algorithms to classify*
508 *acute respiratory distress syndrome phenotypes: a secondary analysis of randomised*
509 *controlled trials*. *Lancet Respir Med*, 2020. **8**(3): p. 247-257.
- 510 35. Injarabian, L., et al., *Neutrophil Metabolic Shift during their Lifecycle: Impact on their*
511 *Survival and Activation*. *Int J Mol Sci*, 2019. **21**(1).

- 512 36. Masso-Silva, J.A., et al., *Increased peripheral blood neutrophil activation phenotypes*
513 *and NETosis in critically ill COVID-19 patients: a case series and review of the*
514 *literature*. Clin Infect Dis, 2021.
- 515 37. Hazeldine, J., et al., *Traumatic Injury and Exposure to Mitochondrial-Derived Damage*
516 *Associated Molecular Patterns Suppresses Neutrophil Extracellular Trap Formation*.
517 Front Immunol, 2019. **10**: p. 685.
- 518 38. Vorobjeva, N.V. and B.V. Chernyak, *NETosis: Molecular Mechanisms, Role in*
519 *Physiology and Pathology*. Biochemistry (Mosc), 2020. **85**(10): p. 1178-1190.
- 520 39. McIlroy, D.J., et al., *Reduced deoxyribonuclease enzyme activity in response to high*
521 *postinjury mitochondrial DNA concentration provides a therapeutic target for Systemic*
522 *Inflammatory Response Syndrome*. J Trauma Acute Care Surg, 2018. **85**(2): p. 354-358.
- 523 40. Feldman, C. and R. Anderson, *The role of co-infections and secondary infections in*
524 *patients with COVID-19*. Pneumonia (Nathan), 2021. **13**(1): p. 5.
- 525 41. Buehler, P.K., et al., *Bacterial pulmonary superinfections are associated with*
526 *unfavourable outcomes in critically ill COVID-19 patients*. medRxiv, 2020.
- 527 42. Zhu, X., et al., *Co-infection with respiratory pathogens among COVID-2019 cases*.
528 Virus Res, 2020. **285**: p. 198005.
- 529 43. Nguyen, G.T., E.R. Green, and J. Meccas, *Neutrophils to the ROScues: Mechanisms of*
530 *NADPH Oxidase Activation and Bacterial Resistance*. Front Cell Infect Microbiol,
531 2017. **7**: p. 373.
- 532 44. Veras, F.P., et al., *SARS-CoV-2-triggered neutrophil extracellular traps mediate*
533 *COVID-19 pathology*. J Exp Med, 2020. **217**(12).
- 534 45. Messner, C.B., et al., *Ultra-High-Throughput Clinical Proteomics Reveals Classifiers*
535 *of COVID-19 Infection*. Cell Syst, 2020. **11**(1): p. 11-24.e4.
- 536 46. Overmyer, K.A., et al., *Large-Scale Multi-omic Analysis of COVID-19 Severity*. Cell
537 Syst, 2021. **12**(1): p. 23-40.e7.
- 538 47. Shen, B., et al., *Proteomic and Metabolomic Characterization of COVID-19 Patient*
539 *Sera*. Cell, 2020. **182**(1): p. 59-72.e15.
- 540 48. Andrew, N. and R.H. Insall, *Chemotaxis in shallow gradients is mediated*
541 *independently of PtdIns 3-kinase by biased choices between random protrusions*. Nat
542 Cell Biol, 2007. **9**(2): p. 193-200.
- 543 49. Lee, W.L., R.E. Harrison, and S. Grinstein, *Phagocytosis by neutrophils*. Microbes
544 Infect, 2003. **5**(14): p. 1299-306.
- 545 50. Stephens, L., C. Ellson, and P. Hawkins, *Roles of PI3Ks in leukocyte chemotaxis and*
546 *phagocytosis*. Curr Opin Cell Biol, 2002. **14**(2): p. 203-13.
- 547 51. Papayannopoulos, V., *Neutrophil extracellular traps in immunity and disease*. Nature
548 reviews immunology, 2018. **18**: p. 134-147.
- 549 52. Erpenbeck, L., et al., *Effect of Adhesion and Substrate Elasticity on Neutrophil*
550 *Extracellular Trap Formation*. Front Immunol, 2019. **10**: p. 2320.
- 551 53. DeSouza-Vieira, T., et al., *Neutrophil extracellular traps release induced by*
552 *Leishmania: role of PI3K γ , ERK, PI3K σ , PKC, and [Ca²⁺]*. J Leukoc Biol, 2016.
553 **100**(4): p. 801-810.
- 554 54. Lewis, S.M., et al., *Expression of CD11c and EMR2 on neutrophils: potential*
555 *diagnostic biomarkers for sepsis and systemic inflammation*. Clin Exp Immunol, 2015.
556 **182**(2): p. 184-94.
- 557 55. Marini, O., et al., *Mature CD10(+) and immature CD10(-) neutrophils present in G-*
558 *CSF-treated donors display opposite effects on T cells*. Blood, 2017. **129**(10): p. 1343-
559 1356.

- 560 56. Martin, C., et al., *Chemokines acting via CXCR2 and CXCR4 control the release of*
561 *neutrophils from the bone marrow and their return following senescence*. *Immunity*,
562 2003. **19**(4): p. 583-93.
- 563 57. Wilk, A.J., et al., *A single-cell atlas of the peripheral immune response in patients with*
564 *severe COVID-19*. *Nat Med*, 2020. **26**(7): p. 1070-1076.
- 565 58. Buckley, C.D., et al., *Identification of a phenotypically and functionally distinct*
566 *population of long-lived neutrophils in a model of reverse endothelial migration*. *J*
567 *Leukoc Biol*, 2006. **79**(2): p. 303-11.
- 568 59. Metzemaekers, M., et al., *Kinetics of peripheral blood neutrophils in severe*
569 *coronavirus disease 2019*. *Clin Transl Immunology*, 2021. **10**(4): p. e1271.
- 570 60. Carvelli, J., et al., *Association of COVID-19 inflammation with activation of the C5a-*
571 *C5aR1 axis*. *Nature*, 2020. **588**(7836): p. 146-150.
- 572 61. Shambat, S.M., et al., *Neutrophil and monocyte dysfunctional effector response*
573 *towards bacterial challenge in critically-ill COVID-19 patients*. *bioRxiv*, 2020.
- 574 62. Blanco-Melo, D., et al., *Imbalanced Host Response to SARS-CoV-2 Drives*
575 *Development of COVID-19*. *Cell*, 2020. **181**(5): p. 1036-1045.e9.
- 576 63. Chalmers, J.D., et al., *Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in*
577 *Bronchiectasis*. *N Engl J Med*, 2020. **383**(22): p. 2127-2137.
- 578 64. Zuo, Y., et al., *Neutrophil extracellular traps and thrombosis in COVID-19*. *J Thromb*
579 *Thrombolysis*, 2021. **51**(2): p. 446-453.

580

581

582

583 **Figure 1 – Patient recruitment**

584 45 patients with COVID-19 were recruited from the Queen Elizabeth Hospital Birmingham,
585 alongside 23 age matched controls. Blood was taken, and neutrophils isolated.

586

587 **Figure 2 – Neutrophil functional responses in COVID-19**

588 **A.** Neutrophil transmigration towards IL-8. Data shows fold change in neutrophils migrated to
589 CXCL-8 compared to vehicle control. AMC, n=18; COVID-19 patients n=28. *p=0.0397, Mann-
590 Whitney U test. **B.** Neutrophil phagocytosis of opsonised *S. pneumoniae* following a 30-
591 minute incubation. Data shows MFI of positive neutrophils. *p=0.0236 Mann-Whitney U test
592 between AMC (n=24) and COVID-19 patients (n=30). **C.** Cytoplasmic ROS levels measured in
593 neutrophils at baseline (0 minutes) and after phagocytosis. Data were analysed by two-way
594 ANOVA *p<0.0235, ***p=0.0005 between time 0 and 30 minutes. **D.** Nuclear/mitochondrial
595 ROS levels in neutrophils at baseline (0 minutes) and after phagocytosis. Data were analysed
596 by two-way ANOVA and post-hoc test *p<0.0001 between time 0 and 30 minutes. ###
597 p<0.0001 between AMC and COVID-19 patients.

598

599 **Figure 3 - NETosis in COVID-19.**

600 **A.** NET release by neutrophils stimulated with PMA for 3 hours, measured as absorbance of
601 cfDNA stained with Sytox green. Data shows fold change in absorbance of PMA stimulated
602 neutrophils compared to vehicle control. Data analysed by Mann-Whitney U test between
603 AMC (n=23) and COVID-19 patients (n=33), *p=0.0366. **B.** Comparison of NET release by
604 activated neutrophils in patients with low 4C (n=8) or high 4C (N=26) score. Data analysed by
605 Mann-Whitney U test, *p=0.0118. **C.** Plasma cell free DNA levels measured by flurometry in
606 AMC (n=23) and COVID-19 patients (n=41). Data analysed by Mann-Whitney U test,
607 *p=0.0153. **D.** Comparison of cfDNA levels measured by flurometry in COVID-19 (N=10) on

608 day 1 and on day 3-5. Data analysed by Wilcoxon test. * $p=0.0186$. **E.** % DNA degradation by
609 serum NETs in AMC (n=23) and COVID-19 (n=41). Data analysed by Mann-Whitney U test
610 *** $p<0.0001$.

611

612 **Figure 4 – Neutrophil phenotype in COVID-19**

613 Expression of cell surface markers on neutrophils measured by flow cytometry. Data shows
614 MFI of CD11b (**A**, $p=0.0003$), CD11c (**B**, $p=0.0008$), % expression of CD54 (**C**, $p<0.0001$) and
615 MFI of CD54 (**D**, $p=0.0008$) in AMC (n=22) and COVID-19 patients (n=34). Data were analysed
616 by Mann-Whitney U test. Expression of CXCR2 (**E**, $p=0.0322$), CXCR4 (**F**, $p=0.0273$) and %
617 expression of CD54 (**G**, $p=0.0420$) on COVID-19 neutrophils on day 1 or follow up (day 3-5).
618 Data are expressed as individual points, analyzed by Wilcoxon test (n=11).

619

620

621 **Figure 5 – Plasma cytokine levels in COVID-19**


622 Plasma concentrations of **A.** IL-6 (**A**, $p=0.009$), VEGF (**B**, $p<0.0001$), sTNFRI (**C**, $p<0.0001$), GM-
623 CSF (**D**, $p=0.3375$) and MPO (**E**, $p<0.0001$) in AMC (n=24) and COVID-19 patients (N=41). Data
624 analysed by Mann-Whitney U test.

625

626 **Figure 6 – Summary of results**

627 Compared to AMC, neutrophils isolated from non-ICU COVID-19 patients demonstrate
628 increased migration, impaired phagocytosis and reduced nuclear/mitochondrial ROS
629 generation. COVID-19 neutrophils have altered phenotype, displaying increased expression
630 of migration markers CD54 and CD11c. COVID-19 patients also display elevated NETosis, both
631 ex vivo and in the circulation, and elevated pro-inflammatory cytokines. This contributes to
632 disease pathogenesis in COVID-19.

633



656 Figure 1

657
658




Figure 2

697





Figure 3

738







Figure 5



831
832

Figure 6